Close Menu

NEW YORK – Ortho Clinical Diagnostics said today that the US Food and Drug Administration has cleared its Ortho Sera suite of reagents that enable extended antigen phenotyping.

The product was cleared for use with the Ortho Vision analyzer.

Ortho said that the reagents cover more than 99 percent of the most commonly tested blood group antigens, providing support for patients with unexpected antibodies. The reagents' antisera additive approach allows extended phenotyping to be personalized according to patient needs, reducing waste, and enhancing efficiency, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Sponsored by

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.